【摘要】 结核病（TB），尤其是耐多药TB(MDR-TB)是近20年全球细菌感染引起死亡的第一杀手，故寻找具有全新作用机制的抗TB新药迫在眉睫。Macozinone（研发代号：PBTZ169）是靶向于DprE1的新型抗MDR-TB候选药物，通过抑制结核分枝杆菌细胞壁的合成发挥杀菌作用，目前处于Ⅱ期临床研究阶段。本文就Macozinone的基本信息、作用机制、临床前研究及临床研究等方面作一概述。更多还原

【Abstract】 Tuberculosis(TB),especially multidrug-resistant TB(MDR-TB),is the leading cause of death from bacterial infections in the past 20 years globally. Thus,there is an urgent need to develop new anti-TB drugs with novel mechanism.Macozinone(development code:PBTZ169),a new anti-MDR-TB candidate targeting DprE1,exerts bactericidal effect through inhibiting the synthesis of Mycobacterial tuberculosis cell wall,is currently being tested in phase Ⅱ clinical trial. Basic information,mechanism of action,pre-clinical and clinical research of Macozinone were summarized in this review.更多还原